NVO logo

Novo Nordisk Community

NYSE:NVO Community
  • 3 Narratives written by author
  • 15 Comments on narratives written by author
  • 605 Fair Values set on narratives written by author

Community Investing Ideas

NVO logo
Novo Nordisk

A Quality Compounder Marked Down on Overblown Fears

Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
57.8% undervalued intrinsic discount
15.71%
Revenue growth p.a.
28users have liked this narrative
8users have commented on this narrative
77users have followed this narrative
10 days ago author updated this narrative
NVO logo
Novo Nordisk

Future PE of 20x Signals Promising Growth for Novo Nordisk

Catalysts ◦ Strong position in the GLP-1 drug market , leading with Ozempic for diabetes and Wegovy for obesity. These products have driven significant growth.
View narrative
US$69.18
FV
26.4% undervalued intrinsic discount
11.06%
Revenue growth p.a.
39users have liked this narrative
7users have commented on this narrative
144users have followed this narrative
15 days ago author updated this narrative
NVO logo
Novo Nordisk

Novo Nordisk will thrive with a 34.7751% profit margin boost

23-apr-2025 Novo Nordisk will face competition in the obisitas and diabetes space. Regulation and insurances may impact its growth.
View narrative
US$65.50
FV
22.2% undervalued intrinsic discount
15.81%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
4 months ago author updated this narrative